Abstract

Malignant neoplasms represent a genuine public medical condition in the modern world. Assessments from the GLOBOCAN project show that in the year 2015 rate and mortality extends an overall frequency of over 15.2 million new instances of malignancy, and deaths of over 8.8 million. Musculoskeletal tumors are moderately uncommon, as they represent 0.2–0.5% of all malignancies in all ages. Nations like India, China and Japan have an exceptionally low occurrence of musculoskeletal tumors, while the most elevated rate is accounted for in Western Europe and the USA, predominantly osteosarcoma and Ewing sarcoma. Upgrades in careful strategies, chemotherapy and radiotherapy have improved the forecast of sarcoma patients, yet have since arrived at a plateau level. Nanotechnology offers solution in different regions of sarcoma treatment including diagnosis and treatment. In orthopaedic oncology nanotechnology can possibly improve finding, beat drug resistance, fundamental harmfulness of typical host cells and all the more adequately provide medications to malignancy cells. This review focuses on tumor targeting by nanoparticles, literature survey on nanotechnological approaches in cancer therapy, role of nanomedicines in diagnosis and treatment of sarcomas, discusses few nano formulations being used in sarcoma. Finally, the potential role of nanotechnology in addressing the challenges of drug and radiotherapy resistance is discussed.